Arrevus
Research Triangle Park, US · Founded 2015 · Delaware corporation
Founders & leadership
RV
Robert V. HouseNamed on SEC filing
CN
Carl N. KrausNamed on SEC filing
Board
BG
Barry GarfinkleBoard director
JM
Joe McMahonBoard director
JW
Joseph W. St. GemeBoard director
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 3 rounds · 2017–2019
▶$150KraisedSep 2019 · 1 investors · BiotechnologyRule 506(b)
▶$150KraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT SCHOTZINGERDirector
- CARL N KRAUSExecutive Officer, Director, Promoter
- ROBERT V HOUSEExecutive Officer, Director, Promoter
- JOSEPH W ST. GEMEDirector
- JOE N MCMAHONDirector
- BARRY GARFINKLEDirector
- DORIS SNOWPromoter
- Offering amount
- $300K
- Amount sold
- $150K
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$300KraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
▶$300KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Doris M. SnowPromoter
- Joe McMahonDirector
- Joseph W. St. GemeDirector
- Barry GarfinkleDirector
- Carl N. KrausExecutive Officer, Director, Promoter
- Robert V. HouseExecutive Officer, Director, Promoter
- Offering amount
- $600K
- Amount sold
- $300K
- Proceeds to insiders
- $30K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1000KraisedMay 2017 · 1 investors · BiotechnologyRule 506(b)
▶$1000KraisedMay 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert V. HouseExecutive Officer, Director, Promoter
- Barry GarfinkleDirector
- Carl N. KrausExecutive Officer, Director, Promoter
- Joe McMahonDirector
- Doris M. SnowPromoter
- Joseph W. St. GemeDirector
- Offering amount
- $1.5M
- Amount sold
- $1000K
- Proceeds to insiders
- $195K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $319.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $319K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $299.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $294.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $297.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $295.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has Arrevus raised?
- Arrevus has disclosed $1.4M raised across 3 rounds.
- Where is Arrevus headquartered?
- Arrevus is headquartered in Research Triangle Park, US.